Mark Taylor has over 20 years in the specialty pharmaceuticals sector serving as a senior executive of several public companies, and as a sell-side pharmaceutical analyst.
Most recently, Mr. Taylor was Senior Vice President of Corporate Development for Obagi Medical Products Inc., the market share leader in physician-dispensed dermatologics.
Valeant Pharmaceuticals International acquired Obagi
in April 2013.
Prior to Obagi, Mr. Taylor was Vice President, Diagnostics for MP Biomedicals, LLC, a privately held global provider of infectious disease screening and confirmatory tests.
Mr. Taylor also served Roth Capital Partners for five years where he held the titles of Managing Director of Healthcare Banking and Senior Pharmaceutical Analyst.
Prior to Roth, Mr. Taylor was head of the largest division at ICN Pharmaceuticals Inc. (now Valeant Pharmaceuticals International) as Executive Vice President, North America.
Under Mr. Taylor's
expanded its dermatology division by adding prescription products, physician dispensed skin care brands, and light activated devices to its portfolio.
Mr. Taylor also served as Vice President of Business Development at Watson Pharmaceuticals (now Allergan plc.), another large dermatology products provider.
During this time Watson made its first foray into dermatology products by acquiring Oclassen Pharmaceuticals, Inc.
Mark is a graduate of Tulane University and serves on the board of Medical Care Corporation, a private company focused on Alzheimer's research and diagnosis.